Elcubragistat is under clinical development by H. Lundbeck and currently in Phase I for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase I drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Elcubragistat LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Elcubragistat overview

Elcubragistat (ABX-1431) is under development for the treatment of post-traumatic stress disorder (PTSD). It is administered through oral route. The drug candidate is a small molecule, acts by targeting endocannabinoid system and is developed based on protein profiling (ABPP) technology. The drug candidate was also under development for the treatment of functional dyspepsia. It is a new chemical entity (NCE).
It was also under development for Tourette syndrome, neuromyelitis optica (Devic’s Syndrome), levodopa-induced dyskinesia, peripheral neuropathic pain, chronic neuropathic pain, hyperalgesia, fibromyalgia, lower limb muscle spasticity in multiple sclerosis and focal epilepsy .

H. Lundbeck overview

H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.

For a complete picture of Elcubragistat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.